drugset / Trial / NCT00295100
Tamoxifen-MRI Study
Phase 2
Completed
78 enrolled
University of Pennsylvania
AstraZeneca · collabNational Cancer Institute (NCI) · collab
RandomizedCrossoverDouble-blindPrevention
Summary
The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial. Study participants will be randomly assigned to receive either tamoxifen or placebo for one year. Participants will subsequently be followed for one year off of medication. The primary objective is to evaluate the effectiveness of tamoxifen in reducing breast density by mammogram.
Timeline
- Start
- 2000-09
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamoxifen | Small molecule | — | — |